Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease-Hope, Reality, and the Unknown Going Forward

被引：0
|
作者：
O'Malley, Patricia Anne [1 ,2 ]
机构：
[1] Premier Hlth Miami Valley Hosp, Dayton, OH USA
[2] Premier Hlth Nursing Res, 1 Wyoming St, Dayton, OH 45409 USA
来源：
CLINICAL NURSE SPECIALIST | 2023年 / 37卷 / 03期
关键词：
D O I：
10.1097/NUR.0000000000000745
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
[No abstract available]
引用
收藏
页码：111 / 113
页数：3
相关论文
共 14 条
  • [1] Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease
    Dhruva, Sanket S.
    Kesselheim, Aaron S.
    Woloshin, Steven
    Ji, Robin Z.
    Lu, Zhigang
    Darrow, Jonathan J.
    Redberg, Rita F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (03) : 614 - 617
  • [2] Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1683): : 129 - 130
  • [3] Amyloid Imaging-Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease-What Lasts Long Finally Becomes Good?
    Barthel, Henryk
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (04) : 503 - 504
  • [4] How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond
    Lythgoe, Mark P.
    Prasad, Vinay
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 68 - 70
  • [5] Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway The Need for Reforms
    Gyawali, Bishal
    Ross, Joseph S.
    Kesselheim, Aaron S.
    JAMA INTERNAL MEDICINE, 2021, 181 (10) : 1275 - 1276
  • [6] New impetus for amyloid-PET imaging following the Food and Drug administration approval of a new Alzheimer's disease treatment
    Balaji, Nikita
    Balachandar, Ramya
    Algodayan, Sarah
    Lilburn, David M. L.
    Fraioli, Francesco
    Bomanji, Jamshed B.
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (06) : 415 - 416
  • [7] Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease
    Schneider, Lon S.
    ALZHEIMERS & DEMENTIA, 2014, 10 (02) : 247 - 250
  • [8] Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs
    Sachs, Rachel E.
    Donohue, Julie M.
    Dusetzina, Stacie B.
    JAMA HEALTH FORUM, 2022, 3 (11): : E224115
  • [9] Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective
    Bobbins, Amy
    Davies, Miranda
    Lynn, Elizabeth
    Roy, Debabrata
    Yeomans, Alison
    Shakir, Saad A. W.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [10] The Food and Drug Administration's early access and fast-track approval initiatives: How have they worked?
    Shulman, SR
    Brown, JS
    FOOD AND DRUG LAW JOURNAL, 1995, 50 (04) : 503 - 531
12